Literature DB >> 8738915

The targeting of somatic hypermutation.

C J Jolly1, S D Wagner, C Rada, N Klix, C Milstein, M S Neuberger.   

Abstract

Somatic hypermutation does not occur randomly within immunoglobulin V genes but, rather, is preferentially targeted to certain nucleotide positions (hot spots) and away from others (cold spots). Cold spots often coincide with residues essential for V gene folding. Hotspots, which appear to be strategically located to favour affinity maturation, are most frequently located in the CDRs (particularly CDR1) though conserved hotspots are also found at the base of FR3. Hotspots are in part created by local DNA sequence and the strong biases of codon usage in V genes indicate that the genes have evolved such that somatic hypermutation is targeted to those parts of the V where it is likely to prove most useful. These features of mutational hotspots and biased codon usage are also evident in V genes of lower animals suggesting that diversification by strategic targeting of non-templated mutation may have evolved early in antigen receptor evolution.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8738915     DOI: 10.1006/smim.1996.0020

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  29 in total

Review 1.  Memory in the B-cell compartment: antibody affinity maturation.

Authors:  M S Neuberger; M R Ehrenstein; C Rada; J Sale; F D Batista; G Williams; C Milstein
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-03-29       Impact factor: 6.237

2.  Induction of Ig somatic hypermutation and class switching in a human monoclonal IgM+ IgD+ B cell line in vitro: definition of the requirements and modalities of hypermutation.

Authors:  H Zan; A Cerutti; P Dramitinos; A Schaffer; Z Li; P Casali
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

3.  Expression of error-prone polymerases in BL2 cells activated for Ig somatic hypermutation.

Authors:  V Poltoratsky; C J Woo; B Tippin; A Martin; M F Goodman; M D Scharff
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

4.  DNA breaks in hypermutating immunoglobulin genes: evidence for a break-and-repair pathway of somatic hypermutation.

Authors:  Q Kong; N Maizels
Journal:  Genetics       Date:  2001-05       Impact factor: 4.562

5.  Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL).

Authors:  Roshini S Abraham; Susan M Geyer; Marina Ramírez-Alvarado; Tammy L Price-Troska; Morie A Gertz; Rafael Fonseca
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

6.  Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selection.

Authors:  Christopher Harp; Jane Lee; Doris Lambracht-Washington; Elizabeth Cameron; Gregory Olsen; Elliot Frohman; Michael Racke; Nancy Monson
Journal:  J Neuroimmunol       Date:  2006-12-13       Impact factor: 3.478

Review 7.  Malleable immunoglobulin genes and hematopathology - the good, the bad, and the ugly: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.

Authors:  Adam Bagg
Journal:  J Mol Diagn       Date:  2008-08-07       Impact factor: 5.568

8.  Both DNA strands of antibody genes are hypermutation targets.

Authors:  C Milstein; M S Neuberger; R Staden
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

9.  The Ig mutator is dependent on the presence, position, and orientation of the large intron enhancer.

Authors:  J Bachl; C Olsson; N Chitkara; M Wabl
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

10.  Overlapping hotspots in CDRs are critical sites for V region diversification.

Authors:  Lirong Wei; Richard Chahwan; Shanzhi Wang; Xiaohua Wang; Phuong T Pham; Myron F Goodman; Aviv Bergman; Matthew D Scharff; Thomas MacCarthy
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.